Holen Sie sich die Stockscreener-App
0.9488
0.95%
0.0089
Handel nachbörslich:
.96
0.0112
+1.18%
Schlusskurs vom Vortag:
$0.9399
Offen:
$0.94
24-Stunden-Volumen:
153.69K
Relative Volume:
0.67
Marktkapitalisierung:
$4.88M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.78M
KGV:
-0.0222
EPS:
-42.6996
Netto-Cashflow:
$-4.67M
1W Leistung:
-1.37%
1M Leistung:
-1.17%
6M Leistung:
-30.74%
1J Leistung:
-8.93%
1-Tages-Spanne:
$0.9144
$1.05
1-Wochen-Bereich:
$0.891
$1.05
52-Wochen-Spanne:
$0.85
$2.30
Clearmind Medicine Inc Stock (CMND) Company Profile
Firmenname
Clearmind Medicine Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CMND mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.9488 | 4.97M | 0 | -6.78M | -4.67M | -42.70 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Clearmind Medicine Inc Aktie (CMND) Neueste Nachrichten
Clearmind Medicine Announces Enrollment Of First Patient In Phase I/Iia Clinical Trial For Alcohol Use Disorder Treatment - marketscreener.com
Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment - The Manila Times
Clearmind Medicine Inc. Begins Phase I/IIa Trial for CMND-100 to Treat Alcohol Use Disorder - Nasdaq
symbol__ Stock Quote Price and Forecast - CNN
Longeveron® to Attend BIO International Convention 2025 - TradingView
SciSparc-Clearmind Collaboration Leads to Publication of - GlobeNewswire
SciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc. - Nasdaq
Clearmind Medicine Announces Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - The Manila Times
SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction - The Manila Times
Helius Medical Technologies, Inc. Announces Reimbursement by Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device - Stock Titan
Evolving Landscape of Mental Health Segment: Key Market Insights of the Latest Published Substance Use Disorders Report — Alcohol Use Disorder, Cocaine Use Disorder, Opioid Use Disorder, and Cannabis Use Disorder | DelveInsight - GlobeNewswire Inc.
Clearmind Medicine files patent for eating disorder treatment - Investing.com
SciSparc and Clearmind file patent for eating disorder treatment - Investing.com
Clearmind Medicine files patent for eating disorder treatment By Investing.com - Investing.com South Africa
SciSparc and Clearmind file patent for eating disorder treatment By Investing.com - Investing.com India
Psychedelic: Clearmind completes clinical site initiations for AUD trial - Yahoo Finance
SciSparc and Clearmind File Patent for Eating Disorder Treatment - TipRanks
Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders - The Manila Times
SciSparc-Clearmind Collaboration Leads to Filing of - GlobeNewswire
Clearmind Medicine Inc. Files International Patent for Novel Treatment of Eating Disorders Using 3-MMC and PEA - Nasdaq
Novel Eating Disorder Treatment Patent Filed for 70M Patient Market | SPRC Stock News - Stock Titan
Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites - The Manila Times
Clearmind Medicine Inc. Initiates Patient Enrollment for Phase I/IIa Clinical Trial in Alcohol Use Disorder - Nasdaq
Clearmind Medicine (NASDAQ:CMND) Stock Price Down 4.8% – Here’s Why - Defense World
Clearmind Medicine Inc (CMND) requires closer examination - uspostnews.com
Clearmind Medicine Inc Inc. (CMND) Price Performance and Its Relation to the Tech Industry - investchronicle.com
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts - TradingView
Clearmind Medicine to Host Live Webinar 'Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts - The Manila Times
Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading - Bluefield Daily Telegraph
Clearmind Medicine Receives Notice Of Allowance For United States Patent Covering Binge Behavior - marketscreener.com
Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior - TradingView
Clearmind Medicine Launches First U.S. Clinical Site For FDA-Approved Alcohol Use Disorder Trial - Nasdaq
Clearmind Medicine begins phase I/IIa trial for AUD treatment - Investing.com
Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism - The Manila Times
Clearmind Medicine Inc. Initiates Phase I/IIa Clinical Trial for CMND-100 in Alcohol Use Disorder at Johns Hopkins University - Nasdaq
Clearmind Medicine Launches First U.S. Clinical Site For Its FDA-Approved Clinical Trial To Combat Alcoholism - MarketScreener
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial - Yahoo Finance
Clearmind Medicine (CMND) Launches U.S. Clinical Trial for Alcoh - GuruFocus
Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder - The Manila Times
Clearmind Medicine files patent for new psychedelic compounds - Investing.com
Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders - The Manila Times
Clearmind Medicine stock hits 52-week low at $0.95 By Investing.com - Investing.com South Africa
Clearmind Medicine stock hits 52-week low at $0.95 - Investing.com Australia
Clearmind launches data system for alcohol addiction trial - Investing.com
Clearmind Implements EDC System To Streamline Phase I/II Trial For Alcohol Use Disorder Drug - Nasdaq
Clearmind Medicine launches EDC system to support Phase I/II trial - TipRanks
Clearmind launches data system for alcohol addiction trial By Investing.com - Investing.com Australia
Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment - The Manila Times
Psychedelic Revolution: Inside Clearmind Medicine's Breakthrough - AInvest
Psychedelic: Exclusive talk with biotech company Clearmind Medicine - Yahoo Finance
Clearmind’s AUD drug candidate arrives in the U.S. for trials By Investing.com - Investing.com South Africa
Finanzdaten der Clearmind Medicine Inc-Aktie (CMND)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
2.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):